Cantor’s Louise Chen dismisses Valeant share weakness today, making a bullish case that the majority of Xifaxan’s sales stem from IBS-D; not Traveler’s Diarrhea.
For GBH Insights’ Daniel Ives, the 4Q showcase is “all about” IBM’s step forward “in the right direction;” an encouraging sign of turnaround momentum entering 2018.
SunTrust’s Youssef Squali Calls BABA; FB; AMZN His Favorite Large-Caps.
BTIG’s Tim Chiang notes that with various positives soaring in Valeant’s favor, these are mostly reflected in the stock’s recently climbing levels.
Shares of Chinanet Online Holdings Inc (NASDAQ:CNET), an integrated online advertising, precision marketing and data-analysis …